243 related articles for article (PubMed ID: 8497860)
1. alpha-Thrombin within fibrin clots: inactivation of thrombin by antithrombin-III.
Naski MC; Shafer JA
Thromb Res; 1993 Mar; 69(5):453-65. PubMed ID: 8497860
[TBL] [Abstract][Full Text] [Related]
2. A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III.
Naski MC; Shafer JA
J Biol Chem; 1991 Jul; 266(20):13003-10. PubMed ID: 2071587
[TBL] [Abstract][Full Text] [Related]
3. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
4. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
5. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
6. The procoagulant effect of zinc on fibrin clot formation.
Marx G; Eldor A
Am J Hematol; 1985 Jun; 19(2):151-9. PubMed ID: 4003387
[TBL] [Abstract][Full Text] [Related]
7. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.
Gandossi E; Lunven C; Berry CN
Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin III: a backward glance o'er travel'd roads.
Seegers WH
Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
[TBL] [Abstract][Full Text] [Related]
10. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Weitz JI; Leslie B; Hudoba M
Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
[TBL] [Abstract][Full Text] [Related]
11. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.
von dem Borne PA; Meijers JC; Bouma BN
Blood; 1995 Oct; 86(8):3035-42. PubMed ID: 7579397
[TBL] [Abstract][Full Text] [Related]
12. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
[TBL] [Abstract][Full Text] [Related]
13. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity.
Kaminski M; Siebenlist KR; Mosesson MW
J Lab Clin Med; 1991 Mar; 117(3):218-25. PubMed ID: 2002278
[TBL] [Abstract][Full Text] [Related]
14. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
15. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
[TBL] [Abstract][Full Text] [Related]
16. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
Hogg PJ; Jackson CM
Proc Natl Acad Sci U S A; 1989 May; 86(10):3619-23. PubMed ID: 2726739
[TBL] [Abstract][Full Text] [Related]
17. Exposure of fibrinogen and thrombin to nitric oxide donor ProliNONOate affects fibrin clot properties.
Helms CC; Kapadia S; Gilmore AC; Lu Z; Basu S; Kim-Shapiro DB
Blood Coagul Fibrinolysis; 2017 Jul; 28(5):356-364. PubMed ID: 27755019
[TBL] [Abstract][Full Text] [Related]
18. Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates.
Haynes LM; Orfeo T; Mann KG; Everse SJ; Brummel-Ziedins KE
Biophys J; 2017 Apr; 112(8):1634-1644. PubMed ID: 28445754
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation and fibrin clot structure.
Wolberg AS
Blood Rev; 2007 May; 21(3):131-42. PubMed ID: 17208341
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
